期刊文献+

China's landscape in oncology drug research:perspectives from research collaboration networks

China's landscape in oncology drug research:perspectives from research collaboration networks
下载PDF
导出
摘要 Objective: Better understanding of China's landscape in oncology drug research is of great significance for discovering anti-cancer drugs in future. This article differs from previous studies by focusing on Chinese oncology drug research communities in co-publication networks at the institutional level. Moreover, this research aims to explore structures and behaviors of relevant research units by thematic community analysis and to address policy recommendations. Methods: This research used social network analysis to define an institutions network and to identify a community network which is characterized by thematic content. Results: A total of 675 sample articles from 2008 through 2012 were retrieved from the Science Citation Index Expanded (SCIE) database of Web of Science, and top institutions and institutional pairs are highlighted for further discussion. Meanwhile, this study revealed that institutions based in the Chinese mainland are located in a relatively central position, Taiwan's institutions are closely assembled on the side, and Hong Kong's units located in the middle of the Chinese mainland's and Taiwan's. Spatial division and institutional hierarchy are still critical barriers to research collaboration in the field of anti-cancer drugs in China. In addition, the communities focusing on hot research areas show the higher nodal degree, whereas communities giving more attention to rare research subjects are relatively marginalized to the periphery of network. Conclusions= This paper offers policy recommendations to accelerate cross-regional cooperation, such as through developing information technology and increasing investment. The brokers should focus more on outreach to other institutions. Finally, participation in topics of common interest is conducive to improved efficiency in research and development (R&D) resource allocation. Objective: Better understanding of China's landscape in oncology drug research is of great significance for discovering anti-cancer drugs in future. This article differs from previous studies by focusing on Chinese oncology drug research communities in co-publication networks at the institutional level. Moreover, this research aims to explore structures and behaviors of relevant research units by thematic community analysis and to address policy recommendations. Methods: This research used social network analysis to define an institutions network and to identify a community network which is characterized by thematic content. Results: A total of 675 sample articles from 2008 through 2012 were retrieved from the Science Citation Index Expanded (SCIE) database of Web of Science, and top institutions and institutional pairs are highlighted for further discussion. Meanwhile, this study revealed that institutions based in the Chinese mainland are located in a relatively central position, Taiwan's institutions are closely assembled on the side, and Hong Kong's units located in the middle of the Chinese mainland's and Taiwan's. Spatial division and institutional hierarchy are still critical barriers to research collaboration in the field of anti-cancer drugs in China. In addition, the communities focusing on hot research areas show the higher nodal degree, whereas communities giving more attention to rare research subjects are relatively marginalized to the periphery of network. Conclusions= This paper offers policy recommendations to accelerate cross-regional cooperation, such as through developing information technology and increasing investment. The brokers should focus more on outreach to other institutions. Finally, participation in topics of common interest is conducive to improved efficiency in research and development (R&D) resource allocation.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2015年第2期138-147,共10页 中国癌症研究(英文版)
基金 the University of Macao for financial support for this research by the project MYRG119(Y1-L3)-ICMS12-HYJ
关键词 ANTI-CANCER pharmaceuticals PUBLICATIONS research collaboration networks thematic analysis Anti-cancer pharmaceuticals publications research collaboration networks thematic analysis
  • 相关文献

参考文献4

二级参考文献27

  • 1张惠荣,姜玉梅.SCI与MEDLINE收录肿瘤学期刊的比较[J].中华医学图书情报杂志,2005,14(1):62-62. 被引量:3
  • 2史春杨,叶协杰.《中国科技期刊研究》2003~2005年载文、作者及引文分析[J].中国科技期刊研究,2007,18(1):65-68. 被引量:62
  • 3游苏宁.应更有效地利用国内的研究成果[J].科技导报,2007,25(10):71-72. 被引量:13
  • 4任江华.井冈山大学严肃处理钟华、刘涛学术造假行为[ EB/OL]. ( 2009-12-29 ) [ 2011-03 -15]. http://society. people.com. cn,/GB/10674914, html.
  • 5洪蔚.科技期刊:科技强国"代言人".科学时报,2010-12-24(A1).
  • 6中国科学技术信息研究所.2006年度中国科技论文统计与分析(年度研究报告)[M].北京:科学技术文献出版社,2008:69.
  • 7丁学东.文献计量学基础[M].北京:北京大学出版社,1992.204-209.
  • 8Science Citation Index Expanded[ DB/OL], [2012-06-15 ]. http://apps, webofknowledge, com/summary, do? product = WOS&doc = 1 &qid = 5 &SID = 2BAmpHLd5 HLEiJcl6LL&search_ mode = AdvancedSearch.
  • 9Journal Citation Reports[ EB/OL]. [2012-07-01 ]. http://admin -apps. weboiknowledge, com/JCR/JCR? RQ = LIST_ SUMMARY _JOURNAL.
  • 10中国科学技术信息研究所.中国科技论文统计结果:2010中国国际科技论文产出情况[M].北京:中国科学技术信息研究所,2010:2-5.

共引文献235

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部